Hassan Amro Metwaly, Shawky Muhammad Abd El-Gawad, Mohammed Ahmed Qasem, Haridy Mustafa Ahmed, Eid Khaled Abd-El-Azeem
Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
Infect Drug Resist. 2019 Jun 5;12:1529-1534. doi: 10.2147/IDR.S202346. eCollection 2019.
infectionis one of the most prevalent chronic bacterial human infections worldwide. colonizes the gastric mucosa and causes persistent gastritis that may progress to gastric cancer. Increased resistance of presents a major problem in most countries. Statins, including simvastatin, which are currently used to treat hypercholesterolemia, appear to have potential synergistic role to antibiotics. This study aimed to assess the value of adding simvastatin as adjuvant to standard triple therapy in patients infected with . This study was conducted on 100 patients diagnosed with by the presence of antigen in stools. All patients were randomly subjected either to the standard triple regimen (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid) (group 1, N=50) or to the standard triple regimen plus simvastatin (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid + simvastatin 20 mg bid) (group 2, N=50). Both groups were treated for 14 days and eradication of was assessed by a stool antigen test 4 weeks after therapy. Eradication of infection was significantly higher in patients treated with the standard triple therapy plus simvastatin (n=41, 82%) than in patients treated with the standard triple therapy (n=31, 62%) (<0.022). Simvastatin significantly improves the eradication rate.
感染是全球最普遍的慢性细菌性人类感染之一。它定植于胃黏膜并导致持续性胃炎，可能会发展为胃癌。在大多数国家，其耐药性增加是一个主要问题。他汀类药物，包括目前用于治疗高胆固醇血症的辛伐他汀，似乎对抗生素具有潜在的协同作用。本研究旨在评估在感染患者中添加辛伐他汀作为标准三联疗法辅助药物的价值。本研究对100例因粪便中存在抗原而被诊断为感染的患者进行。所有患者被随机分为两组，一组接受标准三联疗法（克拉霉素500毫克，每日两次 + 阿莫西林1克，每日两次 + 奥美拉唑20毫克，每日两次）（第1组，N = 50），另一组接受标准三联疗法加辛伐他汀（克拉霉素500毫克，每日两次 + 阿莫西林1克，每日两次 + 奥美拉唑20毫克，每日两次 + 辛伐他汀20毫克，每日两次）（第2组，N = 50）。两组均治疗14天，并在治疗4周后通过粪便抗原试验评估感染的根除情况。接受标准三联疗法加辛伐他汀治疗的患者（n = 41，82%）的感染根除率显著高于接受标准三联疗法治疗的患者（n = 31，62%）（P<0.022）。辛伐他汀显著提高了感染的根除率。
